METHODS FOR TREATING DIABETES

• US 20120027729A1
• Filed: 04/27/2007
• Published: 02/02/2012
• Est. Priority Date: 04/28/2006
• Status: Abandoned Application

• Current Assignee: Administrators Of The Tulane Educational Fund (ADMINISTRATORS|DAVID H. COY)
• Original Assignee: Tulane University Health Sciences Center
• Inventors: Prockop, Darwin J., Lee, Ryang Hwa, Seo, Min Jeong
• Application Number:
  US12/298,606
• Publication Number:
  US 20120027729A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Transplantation of multipotent stromal cells (MSCs) into diabetic mice lowers blood sugar, increases blood insulin levels, increases the number and size of islets, and improves renal pathology. Accordingly, the invention provides methods for treating or preventing diabetes by administering isolated MSCs. The invention also provides methods for treating or preventing complications which arise from diabetes, including diabetic nephropathy, by transplanting isolated MSCs.

Claims

1. A method of treating diabetes in an individual comprising administering to said individual a therapeutically effective amount of isolated multipotent stromal cells.

2. The method of claim 1, wherein the administration of the multipotent stromal cells enhances regeneration of pancreatic islets in the individual.

3. The method of claim 1, wherein the administration of the multipotent stromal cells reduces hyperglycemia in the individual.

4. The method of claim 1, wherein the administration of the multipotent stromal cells increases insulin levels in the individual.

5. The method of claim 1, wherein the administration of the multipotent stromal cells improves the diabetic nephropathy in the individual.

6. The method of claim 1, wherein the multipotent stromal cells are isolated from a tissue selected from the group consisting of bone marrow, peripheral blood, umbilical cord blood, and synovial membrane.

7. The method of claim 6, wherein the multipotent stromal cells are isolated from bone marrow.

8. The method of claim 1, wherein the multipotent stromal cells are cultured in vitro prior to administration to the individual.

9. The method of claim 8, wherein the multipotent stromal cells are expanded in vitro prior to administration to the individual.

10. The method of claim 1, wherein the multipotent stromal cells are autologous.

11. The method of claim 1, wherein the multipotent stromal cells are allogeneic.

12. The method of claim 1, wherein the multipotent stromal cells are HLA compatible with the individual.

13. The method of claim 1, wherein the multipotent stromal cells are isolated from a mammal.

14. The method of claim 13, wherein the mammal is selected from the group consisting of a rodent, a horse, a cow, a pig, a dog, a cat, a non-human primate, and a human.

15. The method of claim 14, wherein the mammal is a human.

16. The method of claim 1, wherein the individual is a mammal.

17. The method of claim 16, wherein the mammal is selected from the group consisting of a rodent, a horse, a cow, a pig, a dog, a cat, a non-human primate, and a human.

18. The method of claim 17, wherein the mammal is a human.

19. The method of claim 1, wherein said administration is by infusion.

20. The method of claim 19, wherein said infusion is selected from the group consisting of intravenous infusion, systemic infusion, intra-arterial infusion, intracoronary infusion, and intracardiac infusion.

21. A method for preventing or inhibiting the progression of a diabetic complication in an individual in need thereof, comprising administering to said individual a therapeutically effective amount of isolated multipotent stromal cells.

22. The method of claim 21, wherein the diabetic complication is a diabetic microvascular complication.

23. The method of claim 22, wherein the diabetic microvascular complication is diabetic nephropathy.

24. The method of claim 22, wherein the diabetic microvascular complication is diabetic neuropathy.

25. The method of claim 22, wherein the diabetic microvascular complication is diabetic retinopathy.

26. The method of claim 21, wherein the diabetic complication is a cardiovascular disease.

27. The method of claim 21, wherein the multipotent stromal cells are isolated from a tissue selected from the group consisting of bone marrow, peripheral blood, umbilical cord blood, and synovial membrane.

28. The method of claim 27, wherein the multipotent stromal cells are isolated from bone marrow.

29. The method of claim 21, wherein the multipotent stromal cells are cultured in vitro prior to administration to the individual.

30. The method of claim 29, wherein the multipotent stromal cells are expanded in vitro prior to administration to the individual.

31. The method of claim 21, wherein the multipotent stromal cells are autologous or allogeneic.

32. A method for reversing hyperglycemia in an individual in need thereof,

comprising administering to said individual a therapeutically effective amount of isolated multipotent stromal cells.

33. The method of claim 32, wherein the hyperglycemia in the individual is caused by diabetes.

34. The method of claim 32, wherein the multipotent stromal cells are isolated from a tissue selected from the group consisting of bone marrow, peripheral blood, umbilical cord blood, and synovial membrane.

35. The method of claim 34, wherein the multipotent stromal cells are isolated from bone marrow.

36. The method of claim 32, wherein the multipotent stromal cells are cultured in vitro prior to administration to the individual.

37. The method of claim 36, wherein the multipotent stromal cells are expanded in vitro prior to administration to the individual.

38. The method of claim 32, wherein the multipotent stromal cells are autologous or allogeneic.

39. A method of reversing hypoinsulinemia in an individual in need thereof, comprising administering to said individual a therapeutically effective amount of isolated multipotent stromal cells.

40. The method of claim 39, wherein the hypoinsulinemia is caused by pancreatic damage.

41. The method of claim 40, wherein the pancreatic damage is caused by diabetes.

42. The method of claim 39, wherein the multipotent stromal cells are isolated from a tissue selected from the group consisting of bone marrow, peripheral blood, umbilical cord blood, and synovial membrane.

43. The method of claim 42, wherein the multipotent stromal cells are isolated from bone marrow.

44. The method of claim 39, wherein the multipotent stromal cells are cultured in vitro prior to administration to the individual.

45. The method of claim 44, wherein the multipotent stromal cells are expanded in vitro prior to administration to the individual.

46. The method of claim 39, wherein the multipotent stromal cells are autologous or allogeneic.

47. A method of enhancing the regeneration or repair of pancreatic islets in an individual in need thereof, comprising administering to the individual a therapeutically-effective amount of isolated multipotent stromal cells.

48. The method of claim 47, wherein the individual has diabetes.

49. The method of claim 47, wherein administration of the multipotent stromal cells increases the number of pancreatic islets in the individual.

50. The method of claim 47, wherein the administration of the multipotent stromal cells increases the size of the pancreatic islets in the individual.

51. The method of claim 47, wherein the multipotent stromal cells are isolated from a tissue selected from the group consisting of bone marrow, peripheral blood, umbilical cord blood, and synovial membrane.

52. The method of claim 51, wherein the multipotent stromal cells are isolated from bone marrow.

53. The method of claim 47, wherein the multipotent stromal cells are cultured in vitro prior to administration to the individual.

54. The method of claim 53, wherein the multipotent stromal cells are expanded in vitro prior to administration to the individual.

55. The method of claim 47, wherein the multipotent stromal cells are autologous or allogeneic.

56. The use of isolated multipotent stromal cells for treating diabetes in an individual in need thereof.

57. The use of isolated multipotent stromal cells in the manufacture of a medicament for treating diabetes in an individual in need thereof.